A5058094909- Rheumatoid Arthritis Research and Therapies
- Systemic Lupus Erythematosus Research
- Adrenal Hormones and Disorders
- Vasculitis and related conditions
- Estrogen and related hormone effects
- Autoimmune and Inflammatory Disorders Research
- Cytokine Signaling Pathways and Interactions
- Bone Metabolism and Diseases
- Urticaria and Related Conditions
- Otitis Media and Relapsing Polychondritis
- Osteoarthritis Treatment and Mechanisms
- Spondyloarthritis Studies and Treatments
- Monoclonal and Polyclonal Antibodies Research
- Coagulation, Bradykinin, Polyphosphates, and Angioedema
- Bone and Joint Diseases
- Biosimilars and Bioanalytical Methods
- Bone health and osteoporosis research
- Asthma and respiratory diseases
- T-cell and B-cell Immunology
- Peripheral Neuropathies and Disorders
- Immune cells in cancer
- Systemic Sclerosis and Related Diseases
- Inflammatory mediators and NSAID effects
- Cancer, Hypoxia, and Metabolism
- Immune Cell Function and Interaction
Charité - Universitätsmedizin Berlin
2016-2025
German Rheumatism Research Centre
2016-2025
Humboldt-Universität zu Berlin
2013-2025
Freie Universität Berlin
2001-2025
Leibniz Association
2021-2025
Berlin Institute of Health at Charité - Universitätsmedizin Berlin
2017-2021
Tel Aviv Sourasky Medical Center
2021
Tel Aviv University
2021
University of Aberdeen
2021
Sana Klinikum Lichtenberg
2018-2019
To provide an update of the European League Against Rheumatism (EULAR) rheumatoid arthritis (RA) management recommendations to account for most recent developments in field.An international task force considered new evidence supporting or contradicting previous and novel therapies strategic insights based on two systematic literature searches efficacy safety disease-modifying antirheumatic drugs (DMARDs) since last (2016) until 2019. A predefined voting process was applied, current levels...
In this article, the 2010 European League against Rheumatism (EULAR) recommendations for management of rheumatoid arthritis (RA) with synthetic and biological disease-modifying antirheumatic drugs (sDMARDs bDMARDs, respectively) have been updated. The 2013 update has developed by an international task force, which based its decisions mostly on evidence from three systematic literature reviews (one each sDMARDs, including glucocorticoids, bDMARDs safety aspects DMARD therapy); treatment...
<h3>Objectives</h3> To provide an update of the EULAR rheumatoid arthritis (RA) management recommendations addressing most recent developments in field. <h3>Methods</h3> An international task force was formed and solicited three systematic literature research activities on safety efficacy disease-modifying antirheumatic drugs (DMARDs) glucocorticoids (GCs). The new evidence discussed light last from 2019. A predefined voting process applied to each overarching principle recommendation....
Since the publication of European League Against Rheumatism (EULAR) recommendations for management large vessel vasculitis (LVV) in 2009, several relevant randomised clinical trials and cohort analyses have been published, which potential to change care therefore supporting need update original recommendations.Using EULAR standardised operating procedures EULAR-endorsed recommendations, task force undertook a systematic literature review sought opinion from 20 experts 13 countries. We...
The rates of different ATP-consuming reactions were measured in concanavalin A-stimulated thymocytes, a model system which more than 80% the ATP consumption can be accounted for. There was clear hierarchy responses energy-consuming to changes energy supply: pathways macromolecule biosynthesis (protein synthesis and RNA/DNA synthesis) most sensitive supply, followed by sodium cycling then calcium across plasma membrane. Mitochondrial proton leak least supply. Control analysis used quantify...
<h3>Objective:</h3> To identify patterns of self-reported health problems relating to dose and duration glucocorticoid intake in unselected patients with rheumatoid arthritis from routine practice. <h3>Methods:</h3> Data 1066 were analysed. The clinical status drug treatment reported by the physician, during past 6 months patient using a comprehensive list symptoms. Patients ongoing for more than current doses less 5, 5–7.5 over 7.5 mg/day prednisone equivalent compared group without any at...
In rheumatology and other medical specialties there is a discrepancy between the widespread use imprecise designation of glucocorticoid treatment regimens. Verbal descriptions regimens used in various phases diseases vary countries institutions. Given this background, workshop under auspices EULAR Standing Committee on International Clinical Studies including Therapeutic Trials was held to discuss issue seek consensus nomenclature for treatment. This report summarises panel9s discussion...
<h3>Objective:</h3> To develop evidence-based recommendations for the management of systemic glucocorticoid (GC) therapy in rheumatic diseases. <h3>Methods:</h3> The multidisciplinary guideline development group from 11 European countries, Canada and USA consisted 15 rheumatologists, 1 internist, rheumatologist–epidemiologist, health professional, patient research fellow. Delphi method was used to agree on 10 key propositions related safe use GCs. A systematic literature search PUBMED,...
Background: A limited number of studies suggest a higher prevalence periodontal disease among individuals with rheumatoid arthritis (RA); however, results have been inconsistent. Further, it is unclear to what extent poor oral hygiene patients RA may account for this association. Methods: The association between and periodontitis was examined in 57 subjects 52 healthy controls, matched by age gender. Oral examination included plaque index (PI), gingival (GI), probing depth (PD), clinical...
Abstract Therapy for polymyalgia rheumatica (PMR) varies widely in clinical practice as international recommendations PMR treatment are not currently available. In this paper, we report the 2015 European League Against Rheumatism (EULAR)/American College of Rheumatology (ACR) management PMR. We used Grading Recommendations, Assessment, Development and Evaluation (GRADE) methodology a framework project. Accordingly, direction strength based on quality evidence, balance between desirable...
Therapy for polymyalgia rheumatica (PMR) varies widely in clinical practice as international recommendations PMR treatment are not currently available. In this paper, we report the 2015 European League Against Rheumatism (EULAR)/American College of Rheumatology (ACR) management PMR. We used Grading Recommendations, Assessment, Development and Evaluation (GRADE) methodology a framework project. Accordingly, direction strength based on quality evidence, balance between desirable undesirable...
To develop recommendations for the management of medium to high-dose (ie, >7.5 mg but ≤100 prednisone equivalent daily) systemic glucocorticoid (GC) therapy in rheumatic diseases. A multidisciplinary EULAR task force was formed, including patients. After discussing results a general initial search on risks GC therapy, each participant contributed 10 propositions key clinical topics concerning safe use GCs. The final were selected via Delphi consensus approach. systematic literature...